Phase 1 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older, of any sex, who are willing and able to sign a consent form.
• People who are expected to live for more than 8 weeks.
• People with a good general level of functioning — specifically, a performance status score of 0 or 1 on the ECOG scale, meaning they are fully active or have only minor limitations in physical activity (confirm with trial site).
• People who have an advanced solid tumour (confirmed by laboratory testing of tissue samples) that has stopped responding to available treatments, or for which no effective treatment exists.
• People whose cancer can be measured using standard imaging criteria known as RECIST 1.1 (confirm with trial site).
• People who are willing to have a tumour biopsy done, or who have a tissue sample from a biopsy taken within the past 3 years that is available for analysis.

Who may not be able to join:

• People with serious ongoing medical conditions, such as heart failure, unstable chest pain, a heart attack within the past 6 months, chronic obstructive pulmonary disease (COPD) with frequent flare-ups, blood pressure that remains very high despite medication, a stroke within the past 6 months, or an active infection that requires intravenous (IV) antibiotics.
• People whose cancer has spread to the brain and is causing symptoms that are not stable — for example, those who are neurologically unstable, currently receiving radiation to the brain, or needing increasing amounts of steroids to manage brain disease. Also excluded are people with brain metastases who have no symptoms but have been on a stable steroid dose for fewer than 14 days before the screening visit.
• People whose blood test results show that their bone marrow, liver, or kidneys are not functioning well enough — including low levels of certain blood cells, poor liver function, or reduced kidney function (specific thresholds apply — confirm with trial site). People who have received a blood transfusion within 2 weeks of the screening date are also excluded under this criterion.
• People with a known history of HIV-1 or HIV-2 infection.
• People with psychiatric conditions that would affect their ability to follow the study procedures or give informed consent.
• People who have had major surgery within 4 weeks before the first dose of the study treatment, or who are still experiencing complications from a recent surgery.
• People who still have significant side effects from previous cancer treatment, surgery, or radiotherapy that have not recovered to a mild or absent level — with the exception of hair loss or changes in skin pigmentation.
• People with underlying health conditions that, in the investigator's opinion, would make the study treatment unsafe or make it difficult to assess side effects.
• People who have received another experimental or commercial cancer treatment within 28 days, or within 5 half-lives of that treatment (whichever is shorter), before the first dose of the study drug. Non-curative radiation therapy for symptom control may be allowed at the investigator's discretion.
• People whom the investigator believes are unlikely to follow the study procedures or requirements.
• People who are pregnant or breastfeeding.
• People of childbearing potential — whether women or men — who are not willing to use effective contraception during the study.
• People who test positive for hepatitis B or hepatitis C with detectable virus levels.
• People who have a known allergy to any ingredient in the study treatment (LXP1788 Injection).

Important: Always verify eligibility with the trial site directly before applying.